Advances in tissue engineering, biomaterials, organs-on-a-chips, and 3D bioprinting are improving the development of biologically accurate reconstructed skin models driving their adoption across various testing environments. For instance, the living human skin-on-a-chip model replicates blood vessels, mimicking the human skin microenvironment closely. These models simulate microvasculature for real-time analysis of transdermal drug delivery.
Growing use of reconstructed skin models in disease modeling and drug discovery is also expected to contribute to the market growth during the forecast period. Reconstructed skin models are gaining traction in disease modeling, particularly in dermatological research, as they can efficiently replicate the pathophysiology of skin conditions like psoriasis, eczema, and skin cancer, thus providing an alternative to animal testing models.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
The global reconstructed skin models market size was valued at USD 37.1 million in 2023 and is anticipated to showcase growth at 14.6% CAGR from 2024
Reconstructed skin models industry from the skin irritation test segment generated USD 9.73 million in 2023, driven by the growing approvals from regulatory authorities, such as EU for reconstructed skin model-based skin irritation test as an alternative to in vivo skin irritation test.
Europe accounted for 37.4% of the reconstructed skin models market share in 2023 and is predicted to reach USD 44.9 million by 2032, owing to the presence of established players in the region.
AIVITA Biomedical, Inc., BICO - THE BIO CONVERGENCE COMPANY, CELLnTEC, EPISKIN, Henkel AG & Co. KGaA, Japan Tissue Engineering Co., Ltd., Mallinckrodt plc, STRATICELL, WEPREDIC Group (Biopredic International) and ZenBio, Inc.